Many patients with secondary progressive multiple sclerosis (SPMS) are actually being misclassified and treated as if they have relapsing-remitting MS (RRMS), which can have an impact on research, treatment, and health care planning, said Jan Hillert, MD, PhD, professor and senior physician at Karolinska Institutet.